{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:35:34Z","timestamp":1793316934467,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1007\/s11910-002-0051-0","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T13:44:43Z","timestamp":1180705483000},"page":"38-43","source":"Crossref","is-referenced-by-count":75,"title":["Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment"],"prefix":"10.1007","volume":"2","author":[{"given":"Paul A.","family":"Lapchak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"51_CR1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/01.STR.20.5.598","volume":"20","author":"Y Okada","year":"1989","unstructured":"Okada Y, Yamaguchi T, Minematsu K, et al.: Hemorrhagic transformation in cerebral embolism. Stroke 1989, 20:598\u2013603.","journal-title":"Stroke"},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/01.STR.24.3.465","volume":"24","author":"CR Hornig","year":"1993","unstructured":"Hornig CR, Bauer T, Simon C, Trittmacher S, Dorndorf W: Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke 1993, 24:465\u2013468.","journal-title":"Stroke"},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/WNL.46.2.341","volume":"46","author":"D Toni","year":"1996","unstructured":"Toni D, Fiorelli M, Bastianello S, et al.: Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996, 46:341\u2013345.","journal-title":"Neurology"},{"key":"51_CR4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","volume":"20","author":"T Brott","year":"1989","unstructured":"Brott T, Adams HP, Olinger CP, et al.: Measurements of acute cerebral infarction: A clinical examination scale. Stroke 1989, 20:864\u2013870.","journal-title":"Stroke"},{"key":"51_CR5","first-page":"92","volume":"10","author":"CM Fisher","year":"1951","unstructured":"Fisher CM, Adams RD: Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropath Exp Neurol 1951, 10:92\u201393.","journal-title":"J Neuropath Exp Neurol"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.28.8.754","volume":"28","author":"JP Mohr","year":"1978","unstructured":"Mohr JP, Caplan LR, Melski JW: The Harvard cooperative stroke registry: a prospective registry. Neurology 1978, 28:754\u2013762.","journal-title":"Neurology"},{"key":"51_CR7","first-page":"1","volume":"5","author":"PD Lyden","year":"1993","unstructured":"Lyden PD, Zivin JA: Hemorrhagic transformation after cerebral ischemia: Mechanisms and incidence. Cerebrovasc Brain Met Rev 1993, 5:1\u201316.","journal-title":"Cerebrovasc Brain Met Rev"},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1161\/01.STR.31.12.3034","volume":"31","author":"PA Lapchak","year":"2000","unstructured":"Lapchak PA, Chapman DF, Zivin JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000, 31:3034\u20133040.","journal-title":"Stroke"},{"key":"51_CR9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/01.STR.32.1.147","volume":"32","author":"PA Lapchak","year":"2001","unstructured":"Lapchak PA, Chapman DF, Zivin JA: Pharmacological effects of the spin trap agents N-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a rabbit thromboembolic model. Combination studies with the thrombolytic tissue plasminogen activator. Stroke 2001, 32:147\u2013153. Study showing differential effects of two classes of spin trap agents on hemorrhage rate.","journal-title":"Stroke"},{"key":"51_CR10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1212\/WNL.48.4.921","volume":"48","author":"GA Rosenberg","year":"1997","unstructured":"Rosenberg GA, Navratil M: Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997, 48:921\u2013926.","journal-title":"Neurology"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1749-6632.1997.tb48386.x","volume":"823","author":"GJ delZoppo","year":"1997","unstructured":"delZoppo GJ: Microvascular responses to cerebral ischemia\/ inflammation. Ann NY Acad Sci. 1997, 823:132\u2013147.","journal-title":"Ann NY Acad Sci"},{"key":"51_CR12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"NINDS rt-PA Stroke Study Group","year":"1995","unstructured":"NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581\u20131587.","journal-title":"N Engl J Med"},{"key":"51_CR13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(97)03022-5","volume":"350","author":"JM Wardlaw","year":"1997","unstructured":"Wardlaw JM, Warlow CP, Counsell C: Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997, 350:607\u2013614.","journal-title":"Lancet"},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","volume":"274","author":"W Hacke","year":"1995","unstructured":"Hacke W, Kaste M, Fieschi C, et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Stroke Study (ECASS). JAMA 1995, 274:1017\u20131025.","journal-title":"JAMA"},{"key":"51_CR15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/WNL.53.1.14","volume":"53","author":"JA Zivin","year":"1999","unstructured":"Zivin JA: Thrombolytic stroke therapy: Past, present, and future. Neurology 1999, 53:14\u201319.","journal-title":"Neurology"},{"key":"51_CR16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0733-8651(18)30033-X","volume":"13","author":"ML Simoons","year":"1995","unstructured":"Simoons ML: Risk-benefit of thrombolysis. Cardiol Clin 1995, 13:339\u2013345.","journal-title":"Cardiol Clin"},{"key":"51_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-7091-6391-7_11","volume":"73","author":"M Chopp","year":"1999","unstructured":"Chopp M, Zhang RL, Zhang ZG, Jiang Q: The clot thickens: thrombolysis and combination therapies. Acta Neurochir Suppl 1999, 73:67\u201371. Article stressing the importance of drug combination therapy for stroke.","journal-title":"Acta Neurochir Suppl"},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.STR.17.4.595","volume":"7","author":"GJ Zoppo del","year":"1986","unstructured":"del Zoppo GJ, Zuemer H, Harker LA: Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986, 7:595\u2013607.","journal-title":"Stroke"},{"key":"51_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/01.STR.29.2.429","volume":"29","author":"JC Grotta","year":"1998","unstructured":"Grotta JC, Alexandov AV: tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke 1998, 29:429\u2013432.","journal-title":"Stroke"},{"key":"51_CR20","first-page":"1382","volume":"43","author":"WC Jean","year":"1998","unstructured":"Jean WC, Spellman SR, Nussbaum ES, Low WC: Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 1998, 43:1382\u20131397.","journal-title":"Neurosurgery"},{"key":"51_CR21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0361-9230(94)90119-8","volume":"35","author":"RK Clark","year":"1994","unstructured":"Clark RK, Lee EV, White RF, et al.: Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue. Brain Res Bull 1994, 35:387\u2013392.","journal-title":"Brain Res Bull"},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1052-3057(99)80001-9","volume":"8","author":"R Egan","year":"1999","unstructured":"Egan R, Lutsep HL, Clark WM, et al.: Open label tissue plasminogen activator for stroke: the Oregon experience. J Stroke Cerebrovasc Dis 1999, 8:287\u2013290.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"51_CR23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1212\/WNL.51.5.1359","volume":"51","author":"LB Morgenstern","year":"1999","unstructured":"Morgenstern LB, Frankowski RF, Shedden P, Pasteur W, Grotta JC: Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial. Neurology 1999, 51:1359\u20131363.","journal-title":"Neurology"},{"key":"51_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-199754010-00002","volume":"54","author":"GJ delZoppo","year":"1997","unstructured":"delZoppo GJ, Wagner S, Tagaya M: Trends and future developments in the pharmacological treatment of acute ischaemic stroke. Drugs 1997, 54:9\u201338.","journal-title":"Drugs"},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM198606263142604","volume":"314","author":"JY Cheung","year":"1986","unstructured":"Cheung JY, Bonventre JV, Malis CD, Leaf A: Calcium and ischemic injury. N Engl J Med 1986, 314:1670\u20131676.","journal-title":"N Engl J Med"},{"key":"51_CR26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0006-8993(00)03294-7","volume":"893","author":"GA Rosenberg","year":"2001","unstructured":"Rosenberg GA, Cunningham LA, Wallace J, et al.: Immunohistochemistry of matrix metalloproteinases in reperfusion injury to the rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 2001, 893:104\u2013112. Original study implicating matrix metalloproteinases (MMP)-3 and MMP-9 in microvascular damage.","journal-title":"Brain Res"},{"key":"51_CR27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/A:1020221919154","volume":"18","author":"F Facchinetti","year":"1998","unstructured":"Facchinetti F, Dawson VL, Dawson TM: Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998, 18:667\u2013682.","journal-title":"Cell Mol Neurobiol"},{"key":"51_CR28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00003643-199605000-00004","volume":"13","author":"BK Siesjo","year":"1996","unstructured":"Siesjo BK, Siesjo P: Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996, 13:247\u2013268.","journal-title":"Eur J Anaesthesiol"},{"key":"51_CR29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/nbdi.1997.0146","volume":"4","author":"A Nakai","year":"1997","unstructured":"Nakai A, Kuroda S, Kristian T, Siesjo BK: The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. Neurobiol Dis 1997, 4:288\u2013300.","journal-title":"Neurobiol Dis"},{"key":"51_CR30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1525-1373.1999.d01-140.x","volume":"222","author":"RA Floyd","year":"1999","unstructured":"Floyd RA: Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999, 222:236\u2013245.","journal-title":"Proc Soc Exp Biol Med"},{"key":"51_CR31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1054\/mehy.1997.0627","volume":"52","author":"KM Anderson","year":"1999","unstructured":"Anderson KM, Ells G, Bonomi P, Harris JE: Free radical spin traps as adjuncts for the prevention and treatment of disease. Med Hypotheses 1999, 52:53\u201357.","journal-title":"Med Hypotheses"},{"key":"51_CR32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0074-7742(08)60725-4","volume":"40","author":"K Hensley","year":"1997","unstructured":"Hensley K, Carney JM, Stewart CA, et al.: Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int Rev Neurobiol 1997, 40:299\u2013317.","journal-title":"Int Rev Neurobiol"},{"key":"51_CR33","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1074\/jbc.271.6.3097","volume":"271","author":"CE Thomas","year":"1996","unstructured":"Thomas CE, Ohlweiler DF, Carr AA, et al.: Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem 1996, 271:3097\u20133104.","journal-title":"J Biol Chem"},{"key":"51_CR34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0006-8993(98)00253-4","volume":"795","author":"J Peeling","year":"1998","unstructured":"Peeling J, Yan HJ, Chen SG, Campbell M, Del Bigio MR: Protective effects of free radical inhibitors in intracerebral hemorrhage in rat. Brain Res 1998, 795:63\u201370.","journal-title":"Brain Res"},{"key":"51_CR35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00004647-200003000-00002","volume":"20","author":"M Asahi","year":"2000","unstructured":"Asahi M, Asahi K, Wang X, Lo EH: Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000, 20:452\u2013457. Preclinical data supporting the development of spin trap agents.","journal-title":"J Cereb Blood Flow Metab"},{"key":"51_CR36","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1212\/WNL.53.9.2140","volume":"53","author":"BR Hu","year":"1999","unstructured":"Hu BR, Liu C, Zivin JA: Reduction of intracerebral hemorrhaging in a rabbit embolic stroke model. Neurology 1999, 53:2140\u20132145.","journal-title":"Neurology"},{"key":"51_CR37","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1073\/pnas.92.11.5057","volume":"92","author":"J Folbergrova","year":"1995","unstructured":"Folbergrova J, Zhao Q, Katsura K, Siesj\u00f6 BK: N-tert-butyl-alphaphenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA 1995, 92:5057\u20135061.","journal-title":"Proc Natl Acad Sci USA"},{"key":"51_CR38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/nbdi.1996.0015","volume":"3","author":"S Kuroda","year":"1996","unstructured":"Kuroda S, Katsura K, Hillered L, et al.: Delayed treatment with a-phenyl-N-tert-butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol Dis 1996, 3:149\u2013157.","journal-title":"Neurobiol Dis"},{"key":"51_CR39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00004647-199907000-00008","volume":"19","author":"S Kuroda","year":"1999","unstructured":"Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999, 19:788\u2013787.","journal-title":"J Cereb Blood Flow Metab"},{"key":"51_CR40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s002210050006","volume":"130","author":"R Schmid-Elsaesser","year":"2000","unstructured":"Schmid-Elsaesser R, Hungerhuber E, Zausinger S, Baethmann A, Reulen HJ: Neuroprotective effects of the novel brain-penetrating antioxidant U-101033E and the spin-trapping agent alpha-phenyl-N-tert-butyl nitrone (PBN). Exp Brain Res 2000, 130:60\u201366.","journal-title":"Exp Brain Res"},{"key":"51_CR41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0891-5849(98)00257-3","volume":"26","author":"M Nakashima","year":"1999","unstructured":"Nakashima M, Niwa M, Iwai T, Uematsu T: Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radical Biol Med 1999, 26:722\u2013729.","journal-title":"Free Radical Biol Med"},{"key":"51_CR42","first-page":"H1986","volume":"272","author":"JB Schulz","year":"1997","unstructured":"Schulz JB, Panahian N, Chen YI, et al.: Facilitation of postischemic reperfusion with alpha-PBN: assessment using NMR and Doppler flow techniques. Am J Physiol 1997, 272:H1986-H1995.","journal-title":"Am J Physiol"},{"key":"51_CR43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0891-5849(96)00039-1","volume":"21","author":"CF Schaefer","year":"1996","unstructured":"Schaefer CF, Janzen EG, West MS, Poyer JL, Kosanke SD: Blood chemistry changes in the rat induced by high doses of nitronyl free radical spin traps. Free Radical Biol Med 1996, 21:427\u2013436.","journal-title":"Free Radical Biol Med"},{"key":"51_CR44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/10715769009145690","volume":"9","author":"GM Chen","year":"1990","unstructured":"Chen GM, Bray TM, Janzen EG, McCay PB: Excretion, metabolism and tissue distribution of a spin trapping agent, alpha-phenyl-N-tert-butyl-nitrone (PBN) in rats. Free Radical Res Comm 1990, 9:317\u2013323.","journal-title":"Free Radical Res Comm"},{"key":"51_CR45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1089\/neu.1995.12.833","volume":"12","author":"GA Rosenberg","year":"1995","unstructured":"Rosenberg GA: Matrix metalloproteinases in brain injury. J. Neurotrauma 1995, 12:833\u2013842.","journal-title":"J. Neurotrauma"},{"key":"51_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1750-3639.1994.tb00825.x","volume":"4","author":"AM Romanic","year":"1994","unstructured":"Romanic AM, Madri JA: Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994, 4:145\u2013156.","journal-title":"Brain Pathol"},{"key":"51_CR47","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/01.STR.29.5.1020","volume":"29","author":"AM Romanic","year":"1998","unstructured":"Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998, 29:1020\u20131030.","journal-title":"Stroke"},{"key":"51_CR48","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2174\/1381612802666221004190555","volume":"2","author":"A Zask","year":"1996","unstructured":"Zask A, Levin JI, Killar LM, Skotnicki JS: Inhibition of matrix metalloproteinases: structure based design. Curr Pharm Des 1996, 2:624\u2013661.","journal-title":"Curr Pharm Des"},{"key":"51_CR49","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/370555a0","volume":"370","author":"AJ Gearing","year":"1994","unstructured":"Gearing AJ, Beckett P, Christodoulou M, et al.: Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature 1994, 370:555\u2013557.","journal-title":"Nature"},{"key":"51_CR50","first-page":"119","volume":"16","author":"M Yamamoto","year":"1999","unstructured":"Yamamoto M, Hirayama R, Naruse K, et al.: Structure-activity relationship of hydroxamate-based inhibitors on membranebound Fas ligand and TNF-alpha processing. Drug Des Discov 1999, 16:119\u2013130.","journal-title":"Drug Des Discov"},{"key":"51_CR51","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/370558a0","volume":"370","author":"GM McGeehan","year":"1994","unstructured":"McGeehan GM, Becherer JD, Bast RC Jr, et al.: Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994, 370:558\u2013561.","journal-title":"Nature"},{"key":"51_CR52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1006\/bbrc.1996.1186","volume":"225","author":"RA Black","year":"1996","unstructured":"Black RA, Durie FH, Otten-Evans C, et al.: Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP. Biochem Biophys Res Comm 1996, 225:400\u2013405.","journal-title":"Biochem Biophys Res Comm"},{"key":"51_CR53","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.162.6.2163","volume":"162","author":"JM Dayer","year":"1985","unstructured":"Dayer JM, Beutler B, Cerami A: Cachectin\/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985, 162:2163\u20132168.","journal-title":"J Exp Med"},{"key":"51_CR54","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/00004647-199811000-00001","volume":"18","author":"S Mun-Bryce","year":"1998","unstructured":"Mun-Bryce S, Rosenberg GA: Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998, 18:1163\u20131172.","journal-title":"J Cereb Blood Flow Metab"},{"key":"51_CR55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(95)01089-0","volume":"703","author":"GA Rosenberg","year":"1995","unstructured":"Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG: Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995, 703:151\u2013155.","journal-title":"Brain Res"},{"key":"51_CR56","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.STR.28.6.1233","volume":"28","author":"FC Barone","year":"1997","unstructured":"Barone FC, Arvin B, White RF, et al.: Tumor necrosis factoralpha. A mediator of focal ischemic brain injury. Stroke 1997, 28:1233\u20131244.","journal-title":"Stroke"},{"key":"51_CR57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF02821717","volume":"19","author":"A Lukes","year":"1999","unstructured":"Lukes A, Mun-Brice S, Lukes M, Rosenberg GA: Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999, 19:267\u2013284.","journal-title":"Mol Neurobiol"},{"key":"51_CR58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0033-0620(99)70003-4","volume":"42","author":"GA Rosenberg","year":"1999","unstructured":"Rosenberg GA: Ischemic brain edema. Prog Cardiovasc Dis 1999, 42:209\u2013216.","journal-title":"Prog Cardiovasc Dis"},{"key":"51_CR59","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/hj.1999.v138.99235","volume":"138","author":"RM Califf","year":"1999","unstructured":"Califf RM: Glycoprotein IIb\/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. Am Heart J 1999, 138:S12-S15.","journal-title":"Am Heart J"},{"key":"51_CR60","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1161\/01.STR.31.6.1402","volume":"31","author":"T Abumiya","year":"2000","unstructured":"Abumiya T, Fitridge R, Mazur C, et al.: Integrin aIIbb3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000, 31:1402\u20131410. New method to increase cerebral vessel patency.","journal-title":"Stroke"},{"key":"51_CR61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00005344-199809000-00021","volume":"32","author":"SS Rebello","year":"1998","unstructured":"Rebello SS, Huang J, Shiu WJ, et al.: Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb\/IIIa receptor antagonist, in anesthetized dogs. J Cardiovasc Pharmacol 1998, 32:485\u2013494.","journal-title":"J Cardiovasc Pharmacol"},{"key":"51_CR62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0049-3848(98)00215-1","volume":"94","author":"S Horisawa","year":"1999","unstructured":"Horisawa S, Kaneko M, Ikeda Y, Ueki Y, Sakurama T: Antithrombotic effect of SM-20302, a nonpeptide GPIIb\/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs. Thrombosis Res 1999, 94:227\u2013234.","journal-title":"Thrombosis Res"},{"key":"51_CR63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(98)00912-1","volume":"366","author":"J Huang","year":"1999","unstructured":"Huang J, Rebello SS, Rosenberg LA, et al.: Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. Eur J Pharmacol 1999, 366:203\u2013213.","journal-title":"Eur J Pharmacol"},{"key":"51_CR64","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1055\/s-0037-1614908","volume":"82","author":"S Horisawa","year":"1999","unstructured":"Horisawa S, Kaneko M, Sakurama T: SM-20302, a nonpeptide GPIIb\/IIIa receptor antagonist, exhibits a wide therapeutic window in a newly developed hemorrhage model in mice. Thromb Haemost 1999, 82:1743\u20131748.","journal-title":"Thromb Haemost"},{"key":"51_CR65","doi-asserted-by":"crossref","unstructured":"Lapchak PA, Araujo DM, Song D, Zivin JA. The nonpeptide GPIIb\/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator (tPA)-induced intracerebral hemorrhage following a thromboembolic stroke. Stroke 2001, in press.","DOI":"10.1161\/hs0102.100530"},{"key":"51_CR66","doi-asserted-by":"crossref","unstructured":"Lapchak PA, Araujo DM: Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 2001, in press.","DOI":"10.2165\/00023210-200115110-00001"},{"key":"51_CR67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/exnr.1996.0137","volume":"141","author":"MP Bowes","year":"1996","unstructured":"Bowes MP, Zivin JA, Thomas GR, Thibodeaux H, Fagan SC: Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol 1996, 141:40\u201346.","journal-title":"Exp Neurol"},{"key":"51_CR68","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1067\/mhj.2000.105107","volume":"139","author":"EJ Topol","year":"2000","unstructured":"Topol EJ, Easton JD, Amarenco P, et al.: Design of the blockade of the glycoprotein IIb\/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J 2000, 139:927\u2013933.","journal-title":"Am Heart J"},{"key":"51_CR69","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0735-1097(00)00554-4","volume":"35","author":"AM Lincoff","year":"2000","unstructured":"Lincoff AM, Califf RM, Topol EJ: Platelet glycoprotein IIb\/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000, 35:1103\u20131115.","journal-title":"J Am Coll Cardiol"},{"key":"51_CR70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/hj.1999.v138.a100461","volume":"138","author":"JC Blankenship","year":"1999","unstructured":"Blankenship JC: Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999, 138:287\u2013296.","journal-title":"Am Heart J"},{"key":"51_CR71","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/hj.1999.v138.a100462","volume":"138","author":"NB Juran","year":"1999","unstructured":"Juran NB: Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. Am Heart J 1999, 138:297\u2013306.","journal-title":"Am Heart J"},{"key":"51_CR72","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00062752-199909000-00011","volume":"6","author":"M Madan","year":"1999","unstructured":"Madan M, Blankenship JC, Berkowitz SD: Bleeding complications with platelet glycoprotein IIb\/IIIa receptor antagonists. Curr Opin Hematol 1999, 6:334\u2013341.","journal-title":"Curr Opin Hematol"},{"key":"51_CR73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/(SICI)1522-726X(200002)49:2<177::AID-CCD13>3.0.CO;2-J","volume":"49","author":"B Vahdat","year":"2000","unstructured":"Vahdat B, Canavy I, Fourcade L, et al.: Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Intervent 2000, 49:177\u2013180.","journal-title":"Catheter Cardiovasc Intervent"},{"key":"51_CR74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1522-726X(200002)49:2<181::AID-CCD14>3.0.CO;2-J","volume":"49","author":"A Ali","year":"2000","unstructured":"Ali A, Patil S, Grady KJ, Schreiber TL: Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb\/IIIa inhibitors. Catheter Cardiovasc Intervent 2000, 49:181\u2013184.","journal-title":"Catheter Cardiovasc Intervent"},{"key":"51_CR75","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.STR.32.2.438","volume":"32","author":"V Larrue","year":"2001","unstructured":"Larrue V, von Kummer R, Muller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. Stroke 2001, 32:438\u2013441. Clinical study dealing with side effects of tissue plasminogen activator.","journal-title":"Stroke"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-002-0051-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-002-0051-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-002-0051-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:05:46Z","timestamp":1683864346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-002-0051-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s11910-002-0051-0","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}